Clinical trials: Vaping Cessation
Addiction Nicotine
The CONQUER Trial - Cessation Of Nicotine, QUitting With E-cigarette Reduction
This clinical trial evaluates the VapeAway system, a novel, multi-modal intervention designed to address the multifaceted nature of vaping addiction.
- Trial name
- CONQUER (NCT07322432)
- Testing
- VapeAway filter system
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- VapeAway
Smoking Cessation
The Effects of Combination Zonisamide and Bupropion on Switching to an Electronic Cigarette
This three-group randomized double-blind placebo-controlled trial (N=180) will evaluate the impact of combination zonisamide and bupropion on the process of switching from combustible cigarettes (CCs) to an e-cigarette.
- Trial name
- NCT05205811
- Testing
- Bupropion, Zonisamide, E-cigarette
- Where
- 2 sites in United States
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Rose Research Center, LLC
NO VAPE + 12 Weeks of Standard CBT, Sham NO VAPE + 12 Weeks Standard CBT
Trial of Novel, On-Demand Virtual Reality to Amplify Practice Efficacy (NO VAPE) Added to Cognitive Behavioral Therapy for Nicotine Vaping Cessation
3. General Description of Study Design The proposed study will evaluate the effect of adding a VR app with CBT-embedded content to a 12-session individual CBT treatment program.
- Trial name
- NO VAPE (NCT07223879)
- Testing
- NO VAPE VR app with CBT-embedded content with a 12-session individual CBT treatment program
- Volunteers
- 90 people
- Sponsor
- Charles River Analytics
Vaping Cessation
Phase 3 Trial Evaluating the Efficacy and Safety of Cytisinicline for Vaping Cessation in Adults Using Nicotine-Containing E Cigarettes
This will be a multi-center, double-blind, randomized, placebo-controlled, Phase 3 study conducted in male or female adults who are daily nicotine e-cigarette users only.
- Trial name
- ORCA-V2 (NCT07392125)
- Testing
- Cytisinicline, Behavioral Support
- Volunteers
- 800 people
- Sponsor
- Achieve Life Sciences
Smoking Cessation
Zonisamide/Bupropion Effects on Switching to Electronic Cigarettes
This single-group, small-scale, open-label study (N= 25 to 50) will evaluate the impact of combination zonisamide and bupropion on the process of switching from combustible cigarettes (CC) to an e-cigarette.
- Trial name
- BuZonE (NCT04388319)
- Testing
- Zonisamide, Bupropion, Halo G6 e-cigarette
- Where
- 2 sites in United States
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Rose Research Center, LLC
Smoking Cessation
Exploratory Study of Switching From Combustible Cigarettes to the BIDI E-cigarette
The aim of this study is to shed light on the importance of nicotine pharmacokinetics in switching to a reduced-harm product by fully matching the nicotine pharmacokinetics of smokers' usual brands of cigarettes.
- Trial name
- NCT05855343
- Testing
- BIDI Stick e-cigarette
- Where
- 2 sites in United States
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Rose Research Center, LLC
Smoking Cessation, Harm Reduction
Assisting Smokers to Switch to a JUUL E-Cigarette by Devaluing Combustible Cigarettes
This study will evaluate a reward devaluation strategy in which smokers use the JUUL e-cigarette immediately before any combustible cigarettes (CCs) are smoked.
- Conditions
- Smoking Cessation, Harm Reduction, E-Cig Use, Cigarette Smoking
- Trial name
- RECON (NCT04188197)
- Testing
- JUUL
- Where
- 2 sites in United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Rose Research Center, LLC
Vaping Cessation
Pilot Study of a Smartphone-Based Vaping Cessation Program
Prospective, open label, single center clinical study enrolling up to 100 participants to evaluate the effect of the Pivot vaping cessation program.
- Trial name
- NCT05642598
- Testing
- Pivot for Vape
- Where
- United States
- Volunteers
- 73 people, healthy volunteers welcome
- Sponsor
- Pivot Health Technologies Inc.
Smoking Cessation, Vaping Cessation
Safety Study of Cytisinicline in Adult Combustible and/or E-cigarette Smokers
Safety assessment of long-term 3 mg cytisinicline three times daily (TID) exposure for 52 weeks is the main purpose of this study, conducted in the United States.
- Trial name
- ORCA-OL (NCT06435221)
- Testing
- Cytisinicline
- Where
- 29 sites in United States
- Volunteers
- 479 people
- Sponsor
- Achieve Life Sciences
Smoking Cessation
Enhanced E-cigarette Coaching Intervention for Dual Users of Cigarettes and E-cigarettes
The purpose of this study is to develop and pilot test an enhanced behavioral coaching intervention for dual users of cigarettes and electronic nicotine delivery systems (ENDS) who call tobacco quitlines for help quitting smoking.
- Trial name
- NCT03575468
- Testing
- Enhanced E-cigarette Coaching, Quitline treatment as usual
- Where
- United States
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- Consumer Wellness Solutions
Vaping, E-Cig Use
A Study of Cytisinicline for Vaping Cessation in Adult Smokers
This placebo-controlled Phase 2 study is being conducted at sites within the United States to evaluate the efficacy and safety profile of 3 mg cytisinicline administered TID for 12 weeks for vaping cessation.
- Trial name
- ORCA-V1 (NCT05431387)
- Testing
- cytisinicline, Behavioral support
- Where
- 5 sites in United States
- Volunteers
- 160 people
- Sponsor
- Achieve Life Sciences